Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

581 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. Kantarjian HM, et al. Among authors: freireich ej. Clin Cancer Res. 2002 Jul;8(7):2177-87. Clin Cancer Res. 2002. PMID: 12114418 Clinical Trial.
Differences in CD33 intensity between various myeloid neoplasms.
Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M, Giles F, Kantarjian H, Cortes J, Thomas D, Keating M, Freireich E, Albitar M. Jilani I, et al. Am J Clin Pathol. 2002 Oct;118(4):560-6. doi: 10.1309/1WMW-CMXX-4WN4-T55U. Am J Clin Pathol. 2002. PMID: 12375643
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM. O'Brien S, et al. Cancer. 2003 Sep 1;98(5):888-93. doi: 10.1002/cncr.11620. Cancer. 2003. PMID: 12942553 Free article. Clinical Trial.
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ. Kantarjian H, et al. Among authors: freireich ej. Cancer. 2004 Dec 15;101(12):2788-801. doi: 10.1002/cncr.20668. Cancer. 2004. PMID: 15481055 Free article. Clinical Trial.
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients.
Tsimberidou AM, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ, Keating MJ, Estey EH. Tsimberidou AM, et al. Among authors: freireich ej. Clin Cancer Res. 2008 Feb 1;14(3):721-30. doi: 10.1158/1078-0432.CCR-07-2063. Clin Cancer Res. 2008. PMID: 18245532
581 results